CEPI announces new collaboration and funding for Lassa vaccine

According to terms of the agreement, Profectus will receive $4.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to support the first phase of its Lassa vaccine project, with an option to invest up to a total of $36 million over five years, which could cover procuring vaccine for stockpiling.

IAVI and the Public Health Agency of Canada Enter into License Agreement for Technology to Enable Lassa Fever Vaccine Development

The International AIDS Vaccine Initiative (IAVI) has entered into a license agreement with the Public Health Agency of Canada (PHAC) toward advancing development, regulatory approval, and supply of a new vaccine candidate against Lassa fever virus

Lessons Learnt from Epidemiological Investigation of Lassa Fever Outbreak in a Southwest State of Nigeria December 2015 to April 2016

One key lesson learnt from the investigation was that the confirmed cases were mainly primary cases; hence the needs to focus on measures of breaking the chain of transmission in the animal-man interphase during Lassa fever epidemic preparedness and response.